---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-038049"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:03:52.775058+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# PMGC subsidiary Northstrive files four new patent applications for EL-22 and EL-32 programs

## Summary
- Filing covers EL-22 in animals (App. 19/191,246) and EL-32 in obesity as monotherapy and with GLP-1 combos.
- New patents also include EL-32 animal feed additive (App. 19/191,258) for muscle growth.
- Northstrive's IP portfolio now totals 8 applications and 5 issued patents covering USA, Japan, Korea, China.
- The filings aim to preserve muscle mass during obesity treatment and expand into animal health market.

## SEC filing metadata
- accession: 0001213900-25-038049
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390025038049/0001213900-25-038049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390025038049/ea0240193-8k_pmgc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-038049
- JSON: https://secwatch.observer/filing/0001213900-25-038049.json
- Plain text: https://secwatch.observer/filing/0001213900-25-038049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.